Abstract:
The purpose of this trial was to assess whether the addition of hyperbaric oxygen to percutaneous coronary intervention can reduce clinical restenosis. Major adverse cardiac events at 8 months were found in only 1 of 24 patients (4%) who received hyperbaric oxygen compared with 13 of 37 patients (35%) who did not.
Sharifi, Fares, Abdel-Karim, Koch, Sopko, Adler, , , (2004). Usefulness of hyperbaric oxygen therapy to inhibit restenosis after percutaneous coronary intervention for acute myocardial infarction or unstable angina pectoris. The American journal of cardiology, 2004 Jun;93(12):1533-5. https://www.ncbi.nlm.nih.gov/pubmed/15194029